ClinicalTrials.gg
RecruitingNCT07699380MetMod-T1DUpdated Sep 15, 2026

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

A Phase 2 interventional study of AMX0035 and Placebo in Type 1 Diabetes (T1D), Metabolic Diseases and Glucose Metabolism Disorders, sponsored by University of Washington. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by University of Washington · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
468th of 1,242
60 · median 40
Started
2026
with 61 others
Phase 2
188 of 1,458
24 open now
Primary completion
2029-12
later than 230 of 256 live
Registered
1,443rd of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 468th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2026, is one of 188 in phase 2, reaches primary completion later than 230 of the 256 other live ones, and was the 1,443rd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

184 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center/Diabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.

Read the detailed description

This is a randomized, double-blind, parallel-group clinical trial to evaluate the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with type 1 diabetes (T1D) (n=30 per arm). Following screening and baseline assessments, eligible participants will be randomized 1:1 to receive either AMX0035 or placebo, with stratification by sex and body mass index (≥30 vs. \<30 kg/m2). Participants will undergo comprehensive metabolic phenotyping at baseline and 24 weeks, including hyperinsulinemic-euglycemic clamp studies, body composition imaging, continuous glucose monitoring, and tissue biopsies (skeletal muscle and adipose) for assessment of mitochondrial function and biological markers. Participants, clinicians administering the intervention, and laboratory personnel analyzing the samples will remain blinded to treatment assignments throughout the study.

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Metabolic Diseases
  • Glucose Metabolism Disorders
  • Endocrine System Diseases
  • Autoimmune Diseases
  • Immune System Diseases
  • Diabetes Melletus, Type 1
  • Nutritional and Metabolic Diseases
  • Combination Therapy
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥18 years to \<70 years of age with established T1D (duration ≥1 year)
  2. Currently on insulin therapy (multiple daily injections or insulin pump)
  3. \<9.5%
  4. 18.5-40 kg/m2
  5. On stable dose of RASB or statin, if indicated
  6. Willing and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  1. History of pancreatic disease (including pancreatitis) or pancreatic surgery
  2. History of cardiovascular disease or stroke within the past 6 months
  3. History of heart failure per criteria
  4. History of severe edema or salt restriction requirement
  5. Biliary disease or pathologies that may alter enterohepatic circulation of bile acids
  6. Estimated (eGFR) \<60 mL/min/1.73m²
  7. Liver disease (/AST >3x [ULN]) or severe hepatic impairment (defined as Class C)
  8. Pregnancy, breastfeeding, or planning pregnancy during the study period
  9. Known to study drug components
  10. Abnormal baseline
  11. Use of off label medications that affect insulin sensitivity within the past 1 month (e.g., metformin, GLP-1RA, SGLT2i, pioglitazone)
  12. Chronic use of anticoagulants
  13. Use of bile acid sequestering agents, inhibitors of bile acid transporters, bile acid derivatives, aluminum-based antacids, probenecid, pan-HDAC inhibitors, phase 2 metabolizing enzymes (e.g., uridine diphosphate glucuronosyl transferases), phase 1 metabolizing enzymes other than cytochrome P450 enzymes (CYPs), and OATP1B3
  14. Use of substrates of CYP2C9, Organic Anion transporter 1, P-glycoprotein, and Breast Cancer Resistance Protein
  15. History of severe hypoglycemia requiring assistance within the past 3 months
  16. History of diabetic ketoacidosis (DKA) within the past 3 months
  17. Personal or family history of breast cancer or ovarian cancer
  18. Current participation in another clinical trial
  19. Any condition(s) found by the study team and confirmed with the Investigator that make it unsafe to participate
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AMX0035

    Participants will be instructed to take one packet of AMX0035 daily for the first 2 weeks, followed by 1 packet twice a day (morning and evening) thereafter for \~6 months.

    Drug: AMX0035

  • Placebo comparator
    Placebo

    Participants will be instructed to take one packet of placebo daily for the first 2 weeks, followed by 1 packet twice a day (morning and evening) thereafter for \~6 months.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in whole-body insulin sensitivity (M-value) measured by hyperinsulinemic-euglycemic clamp

    Evaluate the effect of 24 weeks of AMX0035 versus placebo on whole-body insulin sensitivity in T1D as assessed by gold-standard two-stage hyperinsulinemic-euglycemic clamp. * Two-stage hyperinsulinemic-euglycemic clamp studies will occur at baseline and 24 weeks. * Insulin sensitivity will be quantified using the M-value (glucose infusion rate), normalized to lean body mass measured by dual-energy X-ray absorptiometry (DXA) and insulin concentration.

    Time frame: Baseline, 24 weeks

Secondary outcomes

  1. Changes in glycemic control

    Glycemic control will be evaluated via continuous glucose monitoring (CGM) and HbA1c.

    Time frame: Baseline, 24 weeks

  2. Changes in body composition

    Body composition, including total, regional, visceral, and hepatic fat, will be quantified using DXA and multiparametric MRI.

    Time frame: Baseline, 24 weeks

  3. Changes in immune and metabolic biomarkers

    * Circulating and peripheral blood mononuclear cell (PBMC)-based biomarkers of inflammation and oxidative stress will be measured. * Associations between these biological markers and insulin sensitivity or glycemic metrics will be examined using multivariable models.

    Time frame: Baseline, 24 weeks

  4. Changes in mitochondrial function

    Skeletal muscle and adipose tissue biopsies will be analyzed for ER stress, inflammation, and insulin signaling. Skeletal muscle tissue will also undergo assessment of mitochondrial function by ex vivo respiration.

    Time frame: Baseline, 24 weeks

  5. Establish the safety and tolerability of AMX0035 in adults with T1D

    * Adverse events including hypoglycemia, DKA, and changes in hepatic and renal function will be closely monitored throughout the study. * Tolerability will be assessed through participant-reported symptoms, including gastrointestinal side effects and study discontinuations. * An independent Data Safety Monitoring Board (DSMB) will periodically review unblinded safety data and provide guidance.

    Time frame: Duration of study

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2029, 39 months later.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 39 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 13, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07699380
Collaborators
Breakthrough T1D
Responsible party
Petter Bjornstad (Professor: Division of Metabolism, Endocrinology, and Nutrition, University of Washington) — Principal investigator
First posted
Jul 13, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 15, 2026

Study contacts

Amanda Bard, MMS, MS, CCRC
Contact
abard@uw.edu
206-685-2069
Petter M Bjornstad, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium phenylbutyrate and taurursodiol

Start the discussion